Stock listing

NASDAQ:BLSM BlossomHill Therapeutics, Inc. Stock

Home listing (NASDAQ) of BlossomHill Therapeutics, Inc.

Follow BlossomHill Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BLSM

$14.51 USD -0.08 (-0.5%)

Close on Nov 20, 2026

Past 3 months -9.3% · daily closes, Aug 6, 2026 – Nov 20, 2026, adjusted for splits
Day range
$13.90 – $15.63 USDNov 20, 2026
Volume
270,735 sharesNov 20, 2026
Market cap
$461.2M USDAt the close on Nov 20, 2026 · price × 31.78M shares outstanding
Traded on an average day
$3.52M USDMedian day 170,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BLSM · Home$14.51 USD-0.08 (-0.5%)270,735$14.34$15.63$13.90$14.59Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BLSM · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$14.51-0.08-0.5%$14.34$15.63$13.90270,735
$14.59-0.54-3.6%$15.17$16.75$14.34280,171
$15.13+1.48+10.8%$13.69$15.37$13.09390,259
$13.65-0.37-2.6%$14.00$14.00$13.2698,608
$14.02-0.82-5.5%$15.23$15.68$13.40222,586
$14.84-1.28-7.9%$16.08$16.08$14.51256,382
$16.12+1.88+13.2%$14.48$16.19$14.48203,681
$14.24-0.22-1.5%$13.74$14.56$12.97175,885
$14.46+0.96+7.1%$13.69$15.53$13.69213,183
$13.50+1.15+9.3%$12.29$14.09$12.14174,332
$12.35-0.03-0.2%$12.14$13.03$11.02351,538
$12.38-0.03-0.2%$12.45$13.00$11.24297,390
$12.41-0.01-0.1%$12.38$12.78$12.28158,454
$12.42-1.33-9.7%$13.80$14.23$12.28140,741
$13.75-1.46-9.6%$16.40$16.40$13.51155,794
$15.21-1.25-7.6%$17.00$17.53$14.9098,955
$16.46+0.705+4.5%$15.83$16.63$15.6773,512
$15.76-0.635-3.9%$16.34$16.94$15.6174,206
$16.39+1.76+12.0%$14.53$16.82$14.53204,367
$14.63-1.18-7.5%$15.82$15.82$14.4284,346
$15.81+0.21+1.3%$15.47$16.71$15.4797,971
$15.60+1.20+8.3%$14.54$15.68$14.4776,269
$14.40+0.24+1.7%$14.09$15.05$14.0974,924
$14.16+0.22+1.6%$14.10$14.25$12.93189,368
$13.94-1.04-6.9%$14.79$14.79$13.31293,100
$14.98-0.28-1.8%$15.17$15.53$14.70176,500
$15.26-0.22-1.4%$15.39$15.84$14.77170,200
$15.48-1.79-10.4%$17.25$17.91$15.35118,600
$17.27-0.21-1.2%$17.40$18.22$16.9391,100
$17.48+0.60+3.6%$16.80$17.77$16.68131,800
$16.88+0.27+1.6%$16.52$17.28$16.18165,200
$16.61-0.68-3.9%$17.17$17.67$16.12253,800
$17.29-2.65-13.3%$20.06$20.06$17.06247,400
$19.94+0.25+1.3%$19.72$20.11$19.06201,500
$19.69+1.10+5.9%$18.33$19.86$18.27169,300
$18.59-0.05-0.3%$18.49$19.74$18.46152,600
$18.64-2.73-12.8%$21.24$21.24$18.41362,200
$21.37+0.03+0.1%$21.17$22.20$20.70228,500
$21.34+1.59+8.1%$19.51$21.55$19.01146,400
$19.75-0.72-3.5%$20.46$21.03$19.33203,100
$20.47-1.87-8.4%$22.42$22.63$20.21263,500
$22.34-2.91-11.5%$25.30$25.81$21.88219,400
$25.25-1.55-5.8%$26.37$27.31$25.03246,900
$26.80+1.06+4.1%$26.09$27.99$25.12292,200
$25.74-1.08-4.0%$26.80$27.55$25.41715,100
$26.82+0.57+2.2%$26.49$27.80$25.61247,600
$26.25+4.08+18.4%$22.34$27.11$22.01319,800
$22.17+0.43+2.0%$22.50$23.38$21.71148,800
$21.74+0.88+4.2%$20.90$22.08$20.45254,300
$20.86-0.65-3.0%$21.55$21.90$20.75148,900
$21.51-0.49-2.2%$22.00$22.39$20.68158,900
$22.00-0.93-4.1%$23.00$23.29$21.82136,300
$22.93+0.92+4.2%$22.05$23.37$22.00229,200
$22.01+1.99+9.9%$20.00$22.16$19.36168,700
$20.02+0.64+3.3%$20.31$20.59$19.3997,300
$19.38+0.39+2.1%$19.10$19.91$18.84109,700
$18.99+0.69+3.8%$18.60$19.93$17.98141,200
$18.30-1.26-6.4%$19.57$19.57$17.59101,600
$19.56-0.24-1.2%$19.82$20.61$19.44163,600
$19.80+1.34+7.3%$18.25$19.84$18.25102,400
$18.46+0.04+0.2%$18.58$18.63$17.9655,700
$18.42+2.39+14.9%$16.10$18.80$16.10193,500
$16.03-0.35-2.1%$16.38$16.50$15.94156,000
$16.38+0.58+3.7%$16.00$16.50$15.75111,400
$15.80-0.37-2.3%$16.21$16.27$15.60212,000
Ticker
NASDAQ:BLSM
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All BlossomHill Therapeutics, Inc. news

BlossomHill Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
11 in the last 12 months · 11 in all · newest Nov 12, 2026 · oldest 2026
Decks
6 decks · latest Nov 20, 2026

Where BlossomHill Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BLSM · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BLSMBOATSUnited StatesUSD

Valuation

Price/book 2.2× against a median of 2.5×: 5th lowest of 11 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$259.4M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BlossomHill Therapeutics, Inc. · NASDAQ:BLSMUS$461.2MUS$259.4Mn/an/an/a2.2×n/a0.1×n/a
Sana Biotechnology, Inc. · NASDAQ:SANAUS$476.4MUS$408.5Mn/an/an/a2.6×n/a0.3×2.29
Regenxbio Inc. · NASDAQ:RGNXUS$473.4MUS$289.0Mn/a1.9×n/a3.2×−113.9%0.5×1.60
Monopar Therapeutics Inc. · NASDAQ:MNPRUS$467.6MUS$362.8Mn/an/an/a3.7×n/a0.0×1.18
Neurogene Inc. · NASDAQ:NGNEUS$458.5MUS$106.4Mn/an/an/a1.3×n/a0.0×1.47
Assembly Biosciences, Inc. · NASDAQ:ASMBUS$454.4MUS$142.3Mn/a2.1×n/a1.5×−16.6%0.0×1.00
Shattuck Labs, Inc. · NASDAQ:STTKUS$454.2MUS$260.4Mn/an/an/a2.4×n/a0.0×1.10
G2GBIO, Inc. · KRX:456160US$451.8MUS$290.8Mn/a176×n/a4.3×−793.7%0.0×n/a
DiaMedica Therapeutics Inc. · NASDAQ:DMACUS$445.1MUS$410.4Mn/an/an/a15.5×n/a0.0×1.67
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Capricor Therapeutics, Inc. · NASDAQ:CAPRUS$441.3MUS$335.9Mn/an/an/a2.1×n/a0.4×0.94
Median of the othersUS$454.3MUS$289.9M4.6×2.5×−361.4%0.0×1.21

Forecasts

4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
35.40 USD · Analysts' mean
EPS, year to Dec 2026
-5.09 · 2 analysts

Team and board

Officers

OfficerRole
J. Jean CuiScientific Founder, President and CEO
Jason KeyesExecutive Vice President and Chief Financial Officer
Vincent LiptakExecutive Vice President and General Counsel
Antonio Garrido-MontalbanSenior Vice President, Drug Substance
Ashley PrestonSenior Vice President, Head of Regulatory Affairs and Quality Assurance
Diane WangSenior Vice President, Clinical Pharmacology and Preclinical Development
Eugene Y. RuiSenior Vice President, Chemistry
Geoff OxnardExecutive Vice President and Chief Medical Officer
Jihao ZhouSenior Vice President, Biometrics
Jill Stuart SmithSenior Vice President, Clinical Operations and Project Management
Z. Jesse ShaoSenior Vice President, CMC
Zachary F. ZimmermanSenior Vice President, Clinical Development
Y. Peter LiCofounder and Executive Chairman

Board

DirectorRole
Y. Peter LiCofounder and Executive Chairman
Bihua ChenBoard Member
Carl L. GordonBoard Member
J. Jean CuiScientific Founder, President and CEO
John SchmidBoard Member
Sheila GujrathiBoard Member
Sundeep AgrawalBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026−13.0%
Q2 2026Sep 18, 2026 · Before open−4.0%

Open Events

Decks

DeckKindSlidesDate
AACR Symposium (November 2026)Conference13 slidesNov 20, 2026
WCLC 2026Conference8 slidesNov 20, 2026
WCLC 2026Conference8 slidesSep 14, 2026
ASCO 2026Conference11 slidesSep 9, 2026
Investor Presentation (September 2026)Investor deck37 slidesSeptember 2026
J.P. Morgan 2026 Healthcare ConferenceConference25 slidesJanuary 2026

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$168.3M raised · US$16 a share · J.P. Morgan +4
Dealers: J.P. Morgan (lead), Leerink Partners (lead), Guggenheim Securities (lead), LifeSci Capital (co-lead), H.C. Wainwright & Co. (co-lead)
Sep 18, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Aug 6, 2026.

Price
US$16.00 a share
Shares offered
9,375,000 shares of common stock
Offering size
US$150 million
Underwriters' option
Up to 1,406,250 more shares
Listing
BLSM on the Nasdaq Global Select Market
Underwriters
J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, H.C. Wainwright & Co. · In the order on the cover
Shares delivered
On or about Aug 10, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceApr 24, 2026
Filed publiclyJul 17, 2026
Amended onceAug 3, 2026
Shares registered with an exchangeAug 4, 2026
Declared effective by the SECAug 6, 2026
Final prospectus, with the priceAug 7, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Aug 7, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development56.1M31.8M
Selling, general and administrative7.89M4.59M
Operating income-64.0M-36.4M
Depreciation and amortization441.0K350.0K
EBITDA-63.6M-36.1M
Income before tax-60.6M-30.7M
Net income-60.6M-30.7M
Earnings per share, basic-2.08-1.06

Balance sheet

LineFY2025FY2024
Cash and equivalents136.7M100.1M
Current assets138.8M104.2M
Total assets163.0M106.8M
Accounts payable2.31M849.0K
Current liabilities15.5M6.77M
Total debt22.4M525.0K
Total liabilities294.7M179.7M
Shareholders' equity-131.7M-72.9M
Shares outstanding29.1M29.1M

Cash flow

LineFY2025FY2024
Cash from operations-46.9M-31.4M
Capital spending-1.07M-92.0K
Free cash flow-48.0M-31.5M
Cash from investing-1.07M-92.0K
Cash from financing84.5M17.6M
Change in cash36.5M-13.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportSep 18, 2026Quarterly reportSEC
8-K · Current reportSep 18, 2026ResultsSEC
8-K · Current reportSep 15, 2026Current reportSEC
SCHEDULE 13D · Big-stake noticeAug 18, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 17, 2026Big-stake noticeSEC
All 49 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
4 · Change in ownershipAug 10, 2026Insider tradeSEC
S-8 · Registration statement for employee plansAug 10, 2026Offer documentSEC
8-K · Current reportAug 10, 2026Current reportSEC
424B4 · ProspectusAug 7, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 7, 2026Other filingsSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 6, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringAug 6, 2026Offer documentSEC
CERT · Exchange's certificate of listingAug 6, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 4, 2026Other filingsSEC
S-1/A · Registration statement, amendedAug 3, 2026Offer documentSEC
S-1 · Registration statementJul 16, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 11, 2026Offer documentSEC
DRS · Draft registration statementApr 24, 2026Offer documentSEC
DDec 10, 2025Other filingsSEC
DJan 2, 2024Other filingsSEC
DMar 1, 2021Other filingsSEC
DJan 11, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BlossomHill Therapeutics, Inc.’s releases · as of Sep 30, 2026

Common shares
31,784,909
Fully diluted
31,784,909

Fully diluted

LineSharesAs of
Common shares31,784,909Sep 16, 2026

Share count over time

CountShares
Sep 16, 202631,784,909

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Cormorant Asset Management, LP3.61M11.4%US$67.4MSep 30, 2026
Orbimed Advisors LLC2.71M8.5%US$50.6MSep 30, 2026
Perceptive Advisors LLC1.81M5.7%US$33.8MSep 30, 2026
Vivo Capital, LLC1.49M4.7%US$27.8MSep 30, 2026
Deerfield Management Company, L.P.1.45M4.5%US$27MSep 30, 2026
JPMorgan1.42M4.5%US$30.2MSep 30, 2026
Janus Henderson1.34M4.2%US$24.9MSep 30, 2026
Fidelity1.03M3.2%US$19.1MSep 30, 2026
Vanguard508K1.6%US$9.47MSep 30, 2026
NEXTBio Capital Management LP250K0.79%US$4.66MSep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Silverarc Capital Management, LLC202K0.64%US$3.77MSep 30, 2026
Opaleye Management Inc.175K0.55%US$3.26MSep 30, 2026
BlackRock148K0.46%US$2.75MSep 30, 2026
a16z Capital Management, L.L.C.125K0.39%US$2.33MSep 30, 2026
Geode Capital119K0.37%US$2.22MSep 30, 2026
Monashee Investment Management LLC80,0000.25%US$1.49MSep 30, 2026
Ameriprise73,6910.23%US$1.37MSep 30, 2026
Citadel55,0000.17%US$1.03MSep 30, 2026
Birchview Capital, LP50,0000.16%US$932KSep 30, 2026
Ghisallo Capital Management LLC50,0000.16%US$932KSep 30, 2026
Millennium45,8180.14%US$854KSep 30, 2026
Goldman Sachs30,8050.10%US$574KSep 30, 2026
Walleye Capital LLC28,6590.09%US$534KSep 30, 2026
Squarepoint Ops LLC23,1500.07%US$432KSep 30, 2026
Northern Trust21,3370.07%US$398KSep 30, 2026
State Street17,2000.05%US$321KSep 30, 2026
D. E. Shaw & Co., Inc.12,0340.04%US$224KSep 30, 2026
Jump Financial, LLC10,2230.03%US$191KSep 30, 2026
Schwab10,1940.03%US$190KSep 30, 2026
Two Sigma10,1000.03%US$188KSep 30, 2026
Aster Capital Management (DIFC) Ltd4,8220.02%US$89,882Sep 30, 2026
Morgan Stanley4,6770.01%US$87,180Sep 30, 2026
Legal & General1,612<0.01%US$30,836Sep 30, 2026
Citigroup Inc1,279<0.01%US$23,841Sep 30, 2026
UBS997<0.01%US$18,584Sep 30, 2026
Osaic Holdings, Inc.512<0.01%US$10,941Sep 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
OrbiMed Capital GP VIII LLC
Director
Buy625,000USD 16.00US$10MAug 10, 2026
Gordon Carl L
Director
Buy625,000USD 16.00US$10MAug 10, 2026
Cormorant Private Healthcare Fund VI, LP
10% owner
Buy312,500USD 16.00US$5MAug 10, 2026
Schmid John P.
Director
Buy6,000USD 16.00US$96,000Aug 10, 2026
Keyes Jason A
Officer: Chief Financial Officer
Buy700USD 16.00US$11,200Aug 10, 2026
Liptak Vincent Paul
Officer: General Counsel
Buy2,200USD 16.00US$35,200Aug 10, 2026
Liptak Vincent Paul
Officer: General Counsel
Buy2,500USD 15.80US$39,500Aug 7, 2026

Big stakes

StakeStakeSharesDateFiling
Jingrong Jean Cui12.50%3.97MSep 30, 2026Schedule 13G
Chen Bihua11.80%3.62MAug 6, 2026Schedule 13D
Orbimed Advisors LLC8.90%2.71MAug 10, 2026Schedule 13D
Janus Henderson Group PLC7.80%2.47MSep 30, 2026Schedule 13G
Perceptive Advisors LLC5.90%1.81MAug 7, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
John Schmid
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Apr 1, 2026); Helix Acquisition Corp. III (Director · Since at least Jan 22, 2026); Design Therapeutics, Inc. (Director · Since at least Mar 25, 2021); AnaptysBio, Inc. (Director · Since at least Feb 2, 2018); BridgeBio Oncology Therapeutics, Inc. (Director · Feb 8, 2024 – Feb 8, 2024 · Past); Xeris Biopharma Holdings, Inc. (Director · Oct 5, 2021 – Aug 12, 2024 · Past); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); Poseida Therapeutics Inc (Director · Jul 9, 2020 – Jan 8, 2025 · Past); Neos Therapeutics Inc (Director · Jul 2, 2018 – Mar 19, 2021 · Past)
Director · Since at least Aug 6, 2026
Bihua Chen
Other companies: Helix Acquisition Corp. III (Chairperson and CEO, Director · Since at least Jan 22, 2026); BridgeBio Oncology Therapeutics, Inc. (Director · Since at least Aug 11, 2025); Biomea Fusion, Inc. (Director · Since at least Jun 11, 2025)
Director · Since at least Aug 6, 2026
Jason Keyes
Other companies: Actuate Therapeutics, Inc. (Director · Since at least Aug 12, 2024); Sesen Bio Inc (Director · May 3, 2021 – Jun 22, 2022 · Past); Equillium, Inc. (Chief Financial Officer · Dec 10, 2020 – Feb 14, 2025 · Past)
Chief Financial Officer · Since at least Aug 6, 2026
Carl L. Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Director · Since at least Sep 28, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 21, 2026)
Director · Since at least Aug 10, 2026
Sundeep Agrawal
Other companies: PAVmed Inc. (Director · Since at least Sep 10, 2024); FoxWayne Enterprises Acquisition Corp (Director · Jan 19, 2021 – Jan 19, 2021 · Past)
Board Member · Since at least Aug 6, 2026
Yishan Li
Other companies: Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Apr 16, 2019 · Past)
Executive Chairman, Director · Since at least Aug 6, 2026
Antonio Garrido-MontalbanSenior Vice President, Drug Substance · Since at least Nov 4, 2026
Ashley PrestonSenior Vice President, Head of Regulatory Affairs and Quality Assurance · Since at least Nov 4, 2026
Diane WangSenior Vice President, Clinical Pharmacology and Preclinical Development · Since at least Nov 4, 2026
Eugene Y. RuiSenior Vice President, Chemistry · Since at least Nov 4, 2026
All 21 people
PersonSeat
Geoff OxnardExecutive Vice President and Chief Medical Officer · Since at least Oct 22, 2026
Geoffrey Raymond OxnardChief Medical Officer · Since at least Aug 6, 2026
Jihao ZhouSenior Vice President, Biometrics · Since at least Nov 4, 2026
Jill Stuart SmithSenior Vice President, Clinical Operations and Project Management · Since at least Nov 4, 2026
Jingrong Jean CuiPresident and CEO, Director · Since at least Aug 6, 2026
J. Jean CuiScientific Founder, President and CEO · Since at least Nov 4, 2026
Sheila GujrathiBoard Member · Since at least Nov 5, 2026
Vincent LiptakExecutive Vice President and General Counsel · Since at least Aug 6, 2026
Y. Peter LiCofounder and Executive Chairman · Since at least Nov 5, 2026
Zachary F. ZimmermanSenior Vice President, Clinical Development · Since at least Nov 4, 2026
Z. Jesse ShaoSenior Vice President, CMC · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about BlossomHill Therapeutics, Inc.